A Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK221149A Administered Intravenously and to Investigate the Pharmacokinetics of GSK221149A Administered Orally to Healthy, Pregnant Females With Uncomplicated Pre-term Labor Between 300/7 and 356/7 Weeks' Gestation
Latest Information Update: 28 Jun 2023
Price :
$35 *
At a glance
- Drugs Retosiban (Primary) ; Retosiban (Primary)
- Indications Preterm labour
- Focus Adverse reactions; Pharmacodynamics; Proof of concept
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 05 Jun 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database.
- 29 May 2017 Results of part A of this study (n=29) published in the British Journal of Clinical Pharmacology
- 29 Jun 2012 Planned number of patients changed from 75 to 100 as reported by European Clinical Trials Database.